Zorevunersen is an investigational RNA medicine in late-stage development for Dravet syndrome, with global Phase 3 evaluation underway. Sponsor communications describe it as a potential disease-modifying approach aiming to improve seizure control and neurodevelopmental outcomes beyond symptomatic anti-seizure medicines. It is not yet approved for marketing.
New treatments for rare pediatric neurological conditions show promise, with zorevunersen reducing seizures in Dravet syndrome patients and an SMA therapy under FDA review following stem cell research breakthroughs.
Stoke Therapeutics presented long-term Dravet syndrome data showing up to 80% seizure reductions sustained through three years, outlined its Phase 3 EMPEROR trial design targeting mid-2027 data, and disclosed first patient dosing in its ADOA program.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06872125 |
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome |
RECRUITING | PHASE3 |
